The Motley Fool

Forget cash ISAs! Why bother when you can get 5.5% a year from investing in the GSK share price

Image source: Getty Images.

Here’s a sobering fact for savers: more than a decade after the financial crisis the average cash ISA still pays just 0.88%. And here’s a couple more: last year 10.8m people nonetheless put a mind-boggling £39.8bn into the tax-free savings vehicle. So much money, so little return.

High interest

Today’s low savings rates are like that old joke about the weather: everybody moans but nobody does anything about it. Especially the big high street banks. However, there is something you can do, if you are willing to take on more risk.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

You can claim yields of more than 5% a year by investing in some of the UK’s biggest and best-known companies, such as pharmaceutical giant GlaxoSmithKline (LSE: GSK), which has long been one of the most generous dividend income payers on the FTSE 100.

No guarantees

Glaxo currently yields 5.6%, covered 1.3 times by earnings, far more than you will get from any cash ISA or savings account. Stocks like Glaxo could help you build a second income, but they behave in a different way to cash.

First, dividends are not guaranteed. Companies fund these regular shareholder payouts from their earnings, and if those earnings drop or profits fall for any other reason, they are free to stop them (which doesn’t do much for the share price either).


Most companies try to increase their dividend every year, which can give you a rising income (something you don’t get with cash). Unusually, Glaxo has frozen its dividend at 80p for the last four years, as earnings per share (EPS) stalled and even fell, including a hefty 21% drop in 2015. City analysts currently predict that EPS will remain flat at 0% in 2018, then rise 4% next year.

The challenge Glaxo faces is bringing new pharmaceutical treatments to market, which is how it makes its money. It loses out when blockbuster treatments such as lung drug Advair, big in the US, come off patent allowing rivals to pump out cheaper generic alternatives.

In the pipeline

Advair enjoyed a reprieve in February when Glaxo said no generic rival was likely to emerge this year, although the group’s profits are still being squeezed by growing competition for its key asthma and HIV units.

Investors keep a close eye on Glaxo’s drugs pipeline, and will be pleased to see positive results for asthma treatment Nucala while it seeks approval for a new one-tablet HIV-1 treatment through its subsidiary ViiV Healthcare, but disappointed that its new biologic drug for chronic obstructive pulmonary disease was rejected by the US medical watchdog.

Cashing out

Even a £74bn blue-chip behemoth is not without risk as you can see. Glaxo’s share price has gone nowhere fast for five years, and the stock has lost some of its lustre as a result. On the plus side, it trades at just 12.8 times earnings, below the 15 times usually seen as fair value, so may be a bargain.

If buying individual stocks is too risky for you, spread your risk by investing in high-yield investment trusts instead. They can also help you escape the derisory return on cash.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

harveyj has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.